Skylight Investment

As a newly founded US dollar investment company, Skylight grew out of a well-known Chinese investment company called Taiyou Investment.Taiyou Investment is funded by Mr. Yu longwen, a successful entrepreneur.The second LP of Taiyou is Mr. Yu Minhong, the CEO of New Oriental (NYSE:EDU) The Skylight inherits the plentiful resources that Taiyou has in China.In addition, The Skylight has a very deep cooperation with Zhen Fund, which is generally accepted as the best angel fund in China. https://angel.co/skylight-investment

Grey Chen

Partner

Hongkai He

Venture Partner

Bruce Jiang

Venture Partner

Diana Liu

Venture Partner

Yubo Ruan

Co-Founder

Huiliang Wang

Venture Partner

Cynthia Yu

Advisor

Sky Yu

General Partner

Nick Zhang

Venture Partner

8 past transactions

Tivic Health

Seed Round in 2019
Tivic Health is a bioelectronic therapeutics company. We translate neuroscience into consumer-friendly medical devices, expanding the role of bioelectronic therapies in the healthcare ecosystem. Their first innovation, ClearUP™ Sinus Pain Relief, delivers temporary relief of sinus pain. It’s a small handheld device that’s easy to use, re-usable, and clinically proven. The company received FDA Clearance January 2, 2019 and will be shipping product in September 2019.

Tivic Health

Angel Round in 2017
Tivic Health is a bioelectronic therapeutics company. We translate neuroscience into consumer-friendly medical devices, expanding the role of bioelectronic therapies in the healthcare ecosystem. Their first innovation, ClearUP™ Sinus Pain Relief, delivers temporary relief of sinus pain. It’s a small handheld device that’s easy to use, re-usable, and clinically proven. The company received FDA Clearance January 2, 2019 and will be shipping product in September 2019.

B9

Seed Round in 2022
B9 is an on-demand income streaming platform assisting employees to gain control over their finances, including their ability to receive earned paycheck without having to wait until payday. It provides their customers with suite of financial wellness benefits, and access to modern banking.

Butlr

Seed Round in 2020
Butlr Technologies Inc. operates a wireless-sensor device that collects and transmits information in real-time. The company also enables the optimization of a retail space layout by translating location and duration data into shopping preference and consumer behavior through analysis. It serves customers in retail and hospitality industries. The company was incorporated in 2019 and is based in Burlingame, California.

Deuro

Angel Round in 2018
Our Mission: Let artificial intelligence penetrate to every industry Our Vision: Short-Term: Build an authoritative, reliable, and trustworthy trading platform to link artificial intelligence services by docking buyers and sellers globally. Mid-Term: Empower growth of Chinese AI industry and contribute to the global development of artificial intelligence. Long-Term: Create a global artificial intelligence ecosystem which established, owned, and shared by every people

Cardea Bio

Series A in 2020
Cardea Bio Inc., a biotech company, develops, manufactures, and delivers commercial graphene-based digital biosensor hardware, software, and molecular infrastructure. The company focuses on creating products and applications that enable precision healthcare by improving diagnostic ease, speed, and cost. Its insight biosensors use the conductive and biocompatible nanomaterial graphene to convert biomolecules into digital elements enabling biology to connect directly to digital networks and creating access to biological data. The company was founded in 2013 and is headquartered in San Diego, California.

Tivic Health

Private Placement in 2019
Tivic Health is a bioelectronic therapeutics company. We translate neuroscience into consumer-friendly medical devices, expanding the role of bioelectronic therapies in the healthcare ecosystem. Their first innovation, ClearUP™ Sinus Pain Relief, delivers temporary relief of sinus pain. It’s a small handheld device that’s easy to use, re-usable, and clinically proven. The company received FDA Clearance January 2, 2019 and will be shipping product in September 2019.

Valitor

Series A in 2018
Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. Their technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. They currently have three development pipelines in the fields of dermatology, ophthalmology, and orthopedics that highlight the capabilities of their novel drug products. ​